RBC Capital lowered the firm’s price target on Regeneron (REGN) to $1,045 from $1,059 but keeps an Outperform rating on the shares. The ...

In a report released on February 3, Akash Tewari from Jefferies maintained a Buy rating on Regeneron (REGN – Research Report), with a price ...

BofA raised the firm’s price target on Regeneron (REGN) to $575 from $565 and keeps an Underperform rating on the shares. Q4 results were ...

Q4 2024 Earnings Call Transcript February 4, 2025 Operator: Hello, and welcome to Regeneron Pharmaceuticals Fourth Quarter ...

Baird lowered the firm’s price target on Regeneron (REGN) to $759 from $940 and keeps a Neutral rating on the shares. The firms lower target ...

In a report released today, Srikripa Devarakonda from Truist Financial reiterated a Buy rating on Regeneron (REGN – Research Report), with a ...

News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter and ...

Pharmaceuticals stock, reducing the price target from $1,185.00 to $1,150.00. Despite the decrease, the firm maintained its Overweight rating on the NASDAQ-listed company. According to InvestingPro ...

NEW YORK, NY / ACCESS Newswire / February 4, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and ...

Regeneron Pharmaceuticals, Inc. (REGN) is currently at $700.00, up $33.15 or 4.97% --Would be highest close since Jan. 15, 2025, when it closed at $703.43 --On pace for largest percent increase since ...

The S&P 500 Index ($SPX) (SPY) today is up +0.58%, the Dow Jones Industrials Index ($DOWI) (DIA) is up +0.09%, and the Nasdaq ...